



M E M O R A N D U M

TO: MEMBERS, GOVERNING BOARD, CALIFORNIA
INSTITUTE FOR REGENERATIVE MEDICINE

FROM: ROBERT N. KLEIN, CHAIR, GOVERNING BOARD
ART TORRES, VICE CHAIR, GOVERNING BOARD
DUANE ROTH, VICE CHAIR, GOVERNING BOARD
JEFF SHEEHY, VICE CHAIR, GRANTS WORKING
GROUP

SUBJECT: CIRM TARGETED CLINICAL DEVELOPMENT AWARDS
(RFA 10-03)

DATE: MARCH 4, 2011

We plan to conduct our review of applications for the Targeted Clinical Development Awards (RFA 10-03) in May, when we meet to consider the Grants Working Group's recommendations. This will be the first time the Board has considered requests for funding human clinical research. Since the applications involve proprietary data, we have decided to schedule a closed session during the Board's March meeting to help ensure that the Board has sufficient time to evaluate proprietary data before considering the Grants Working Group's recommendations. As always, public summaries regarding the applications and the Grants Working Group's review will be presented in advance of the May meeting (unless applications are withdrawn), and the Board will have a second opportunity, if necessary, to consider proprietary information in a closed session before deliberating and making its funding decisions.

We recognize that this two step process is a change from the manner in which we normally consider applications, but given the complexity and proprietary nature of the applications for human clinical research, we believe that the additional closed session will help ensure that the Board has sufficient information upon which to make its decision. In addition, we are proceeding on a trial basis and if the Board determines that this additional step is not necessary, we can modify the procedure in the future.

We look forward to seeing you on March 10th.